17:23 , Sep 28, 2018 |  BC Week In Review  |  Clinical News

Bemcentinib combo posts 30% ORR in PD-L1-negative NSCLC

BerGenBio ASA (OSE:BGBIO) reported data from 10 evaluable previously treated patients with PD-L1-negative non-small cell lung cancer (NSCLC) in the Phase II BGBC008 trial showing that bemcentinib (BGB324) plus Keytruda pembrolizumab led to a best...
19:34 , Sep 25, 2018 |  BC Extra  |  Clinical News

Bemcentinib combo posts 30% ORR in PD-L1-negative NSCLC

BerGenBio ASA (OSE:BGBIO) reported data from 10 evaluable previously treated patients with PD-L1-negative non-small cell lung cancer in the Phase II BGBC008 trial showing that bemcentinib (BGB324) plus Keytruda pembrolizumab led to a best overall...
17:54 , Jun 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer In vitro, cell culture and mouse studies identified two benzenesulfonamide-based AXL inhibitors that could help treat breast cancer. Chemical synthesis and in vitro enzymatic activity assays of benzenesulfonamide analogs yielded two compounds that...
19:20 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

BerGenBio reports Phase Ib/II data for bemcentinib in melanoma

BerGenBio ASA (OSE:BGBIO) reported data from 19 patients with metastatic melanoma in a Phase Ib/II trial evaluating bemcentinib (BGB324) plus PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) or Tafinlar dabrafenib/Mekinist trametinib from...
18:52 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

BerGenBio reports Phase II data for bemcentinib plus Keytruda in NSCLC

BerGenBio ASA (OSE:BGBIO) reported data from 15 evaluable patients with advanced non-small cell lung cancer (NSCLC) in the Phase II BGBC008 trial showing that once-daily 200 mg oral bemcentinib (BGB324) plus PD-1 inhibitor Keytruda pembrolizumab...
20:17 , Feb 2, 2018 |  BC Week In Review  |  Clinical News

BerGenBio reports Phase II data for AXL inhibitor

BerGenBio ASA (OSE:BGBIO) reported data from its Phase II trials of bemcentinib (BGB324) to treat acute myelogenous leukemia (AML) and other cancers. Data were presented at the ASCO-SITC Clinical Immuno-Oncology Symposium in San Francisco. Among 35...
21:35 , Jan 29, 2018 |  BC Extra  |  Clinical News

BerGenBio gains on Phase II data for AXL inhibitor

BerGenBio ASA (OSE:BGBIO) gained NOK5.80 (16%) to NOK41 on Monday after it reported data from its Phase II trials of bemcentinib (BGB324) to treat acute myelogenous leukemia (AML) and other cancers. Data were presented at...
08:20 , Jan 26, 2018 |  BC Week In Review  |  Clinical News

BerGenBio reports Phase I/II data for BGB324

BerGenBio ASA (OSE:BGBIO) said daily 200 mg bemcentinib (BGB324) plus EGFR inhibitor Tarceva erlotinib met the initial efficacy endpoint in the first stage of the Phase II portion of the Phase I/II BGBC004 trial to...
16:03 , Jan 15, 2018 |  BC Extra  |  Preclinical News

Combination therapy could treat tumors resistant to MAPK pathway inhibitors

In a study published in Nature Medicine, Genmab A/S (CSE:GEN; Pink:GMXAY) and academic researchers identified a combination therapy approach that could combat drug resistance in heterogeneous tumors. Melanoma tumors with BRAF mutations that are -- or...
19:58 , Nov 17, 2017 |  BC Week In Review  |  Clinical News

BerGenBio starts Phase II of BGB324 to treat TNBC

BerGenBio ASA (OSE:BGBIO) began a Phase II trial evaluating BGB324 in combination with Keytruda pembrolizumab in up to 56 patients with previously treated, locally advanced or metastatic triple-negative breast cancer (TNBC) or triple negative inflammatory...